With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1204-75-7,3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid,as a common compound, the synthetic route is as follows.
The resulting compound (200 mg, 0.580 mmol) was condensed with 3-hydroxyquinoxaline-2-carboxylic acid (110 mg, 0.580 mmol) to afford the desired title compound (143 mg, yield 51%) as a pale yellow solid. 1H-NMR (CDCl3 400 MHz) delta: 12.90 and 10.21 (1H, brs), 8.05-7.97 (2H, m), 7.61 (1H, d, J=6.8 Hz), 7.58 (1H, m), 7.37 (1H, brs), 7.21-7.13 (2H, m), 5.14-5.07 (1H, m), 4.68 and 4.59 (1H, m), 4.34 (1H, d, J=11.7 Hz), 3.60-3.35 (2H, m), 3.10-2.96 (1H, m), 3.10-2.96 (1H, m), 2.38-2.29 (1H, m), 2.11-0.96 (5H, m), 1.12-1.09 (6H, m). IR (ATR) cm-1: 1680, 1630, 1595, 1525, 1505, 1475. MS (ESI, m/z): 479 (M+H)+. Anal. Calcd for C26H27FN4O4¡¤0.5H2O: C, 64.05; H, 5.79; N, 11.49. Found: C, 64.20; H, 5.58; N, 11.34.
1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various.
Reference£º
Patent; Daiichi Sankyo Company, Limited; EP2258697; (2010); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider